세계의 전이성 흑색종 치료제 시장 보고서(2025년)

Metastatic melanoma therapeutics encompass a range of treatment options available for individuals diagnosed with metastatic melanoma, a type of skin cancer that has spread to other parts of the body. Melanoma arises from the transformation of pigmented cells called melanocytes, leading to the formation of tumors.

The primary types of metastatic melanoma therapeutics include chemotherapy, immunotherapy, targeted therapy, radiation therapy, and surgery. Chemotherapy involves the use of potent chemicals to eliminate rapidly proliferating cells in the body. The treatment may be administered at various stages, including stage 0, stage I, stage II, stage III, and stage IV, depending on the extent of the cancer. These therapeutic options are utilized by various healthcare providers, including hospitals, specialty clinics, home healthcare, and other medical facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The metastatic melanoma therapeutics market research report is one of a series of new reports from The Business Research Company that provides metastatic melanoma therapeutics market statistics, including metastatic melanoma therapeutics industry global market size, regional shares, competitors with a metastatic melanoma therapeutics market share, detailed metastatic melanoma therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the metastatic melanoma therapeutics industry. This metastatic melanoma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The metastatic melanoma therapeutics market size has grown rapidly in recent years. It will grow from $8.28 billion in 2024 to $9.29 billion in 2025 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to pioneering immunotherapy approval, targeted therapy innovations, clinical trial successes, introduction of combination therapies, advancements in diagnostic technologies.

The metastatic melanoma therapeutics market size is expected to see rapid growth in the next few years. It will grow to $14.64 billion in 2029 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to expanding patient pool, research and development initiatives, biomarker identification, accelerated regulatory approvals, market expansion into emerging economies. Major trends in the forecast period include immunotherapy combinations, precision medicine advances, emerging targeted therapies, adjuvant therapies after surgery, development of bi-specific antibodies.

The forecast of 12.1% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. immunotherapy access by increasing costs for PD-1 checkpoint inhibitors and BRAF/MEK inhibitor combinations imported from the UK and Singapore, potentially compromising survival outcomes and raising melanoma treatment costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated growth in the metastatic melanoma therapeutics market is expected to be propelled by two significant factors. Firstly, the rising incidence of melanoma cases is poised to contribute to market expansion. Melanoma, a form of skin cancer originating in melanocytes, the pigment-regulating cells in the skin, can occur anywhere on the skin. Metastatic melanoma therapeutics encompass various treatments designed to block mutant chemicals and impede the growth of melanoma cells while minimizing harm to healthy tissue. According to the American Cancer Society, it is estimated that there will be 58,120 new cases of melanomas diagnosed in males and 39,490 in females in the US in 2023, totaling around 97,610 cases, with approximately 7,990 predicted deaths. The rising incidence of melanoma is a key driver for the growth of the metastatic melanoma therapeutics market.

The growing demand for biologics is expected to further propel market growth. Biologics, therapeutic products derived from living organisms or containing components of living organisms, have transformed the treatment landscape for metastatic melanoma. They offer targeted and immunotherapy-based approaches that have significantly improved patient outcomes with minimal side effects compared to traditional chemotherapy. For instance, according to the US Food and Drug Administration reported that by the end of 2022, 40 biosimilars had received approval, with 27 of them available in the United States, providing alternatives to 10 brand-name biologics. The growing demand for biologics, with their targeted and immunotherapy benefits, is a significant driver for the metastatic melanoma therapeutics market.

The metastatic melanoma therapeutics market is currently witnessing a significant trend towards product innovations, with companies strategically leveraging recent technologies to enhance their market standing. Notably, in January 2022, UK-based biotechnology firm Immunocore obtained FDA approval for KIMMTRAK, the first-ever FDA-approved T cell receptor (TCR) therapy designed for treating unresectable or metastatic uveal melanoma. Developed using Immunocore's ImmTAC technology platform, KIMMTRAK demonstrated a noteworthy overall survival (OS) advantage, boasting a hazard ratio of 0.51 and a median OS of nearly 22 months.

Leading companies in the metastatic melanoma therapeutics sector are actively engaging in strategic collaborations to assess treatments for metastatic cutaneous melanoma. An example of this is the collaboration between Immunocore and Sanofi, announced in June 2022. The partnership involves a clinical trial collaboration and supply agreement, wherein Sanofi will evaluate its engineered IL-2, SAR444245, in combination with Immunocore's KIMMTRAK in patients with advanced unresectable or metastatic skin cancers.

In April 2022, Germany-based investment firm EMZ Partners acquired a majority stake in FotoFinder Systems GmbH, a move undisclosed in terms of financial details. This strategic partnership aims to facilitate FotoFinder Systems GmbH's expansion of its product portfolio and market reach. FotoFinder Systems GmbH specializes in providing skin visualization equipment utilized in melanoma therapeutics.

Major companies operating in the metastatic melanoma therapeutics market include Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Ltd., Eisai Co. Ltd., Incyte Corporation, Exelixis Inc., BeiGene Ltd, Immunocore Holdings plc, Genentech Inc., Iovance Biotherapeutics Inc., Nektar Therapeutics, Adaptimmune Therapeutics plc, AIVITA Biomedical Inc., Idera Pharmaceuticals Inc., Evaxion Biotech A/S, AB Science, AgonOX Inc., InxMed Co. Ltd., NewLink Genetics Corporation, Vical Inc.

North America was the largest region in the metastatic melanoma therapeutics market in 2024. The regions covered in the metastatic melanoma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the metastatic melanoma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The metastatic melanoma therapeutics market consists of sales of surgical resection, lymph node dissection, and lymphatic mapping and sentinel lymph node biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. The metastatic melanoma therapeutics market also includes sales of trametinib (Mekinist), cobimetinib (Cotellic), and binimetinib (Mektovi). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Metastatic Melanoma Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on metastatic melanoma therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for metastatic melanoma therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The metastatic melanoma therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapy: Chemotherapy; Immunotherapy; Targeted Therapy; Radiation Therapy; Surgery
• 2) By Stages: Stage 0; Stage I; Stage II; Stage III; Stage IV
• 3) By End User: Hospitals; Specialty Clinics; Home Healthcare; Other End-Users
• Subsegments:
• 1) By Chemotherapy: Dacarbazine; Temozolomide; Carboplatin And Cisplatin Combinations
• 2) By Immunotherapy: Checkpoint Inhibitors; Interleukin-2 (IL-2); Oncolytic Virus Therapies
• 3) By Targeted Therapy: BRAF Inhibitors; MEK Inhibitors; KIT Inhibitors
• 4) By Radiation Therapy: Stereotactic Radiosurgery; Palliative Radiation Therapy
• 5) By Surgery: Tumor Resection; Sentinel Lymph Node Biopsy; Debulking Surgery
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; AbbVie Inc.; Novartis AG; Bristol-Myers Squibb Company; AstraZeneca PLC; GlaxoSmithKline PLC; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Amgen Inc.; Regeneron Pharmaceuticals Inc.; Daiichi Sankyo Company Ltd.; Eisai Co. Ltd.; Incyte Corporation; Exelixis Inc.; BeiGene Ltd; Immunocore Holdings plc; Genentech Inc.; Iovance Biotherapeutics Inc.; Nektar Therapeutics; Adaptimmune Therapeutics plc; AIVITA Biomedical Inc.; Idera Pharmaceuticals Inc.; Evaxion Biotech A/S; AB Science; AgonOX Inc.; InxMed Co. Ltd.; NewLink Genetics Corporation; Vical Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Metastatic Melanoma Therapeutics Market Characteristics

3. Metastatic Melanoma Therapeutics Market Trends And Strategies

4. Metastatic Melanoma Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Metastatic Melanoma Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Metastatic Melanoma Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Metastatic Melanoma Therapeutics Market Growth Rate Analysis
• 5.4. Global Metastatic Melanoma Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Metastatic Melanoma Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Metastatic Melanoma Therapeutics Total Addressable Market (TAM)

6. Metastatic Melanoma Therapeutics Market Segmentation

• 6.1. Global Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Radiation Therapy
• Surgery
• 6.2. Global Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Stage 0
• Stage I
• Stage II
• Stage III
• Stage IV
• 6.3. Global Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Home Healthcare
• Other End-Users
• 6.4. Global Metastatic Melanoma Therapeutics Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dacarbazine
• Temozolomide
• Carboplatin And Cisplatin Combinations
• 6.5. Global Metastatic Melanoma Therapeutics Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Checkpoint Inhibitors
• Interleukin-2 (IL-2)
• Oncolytic Virus Therapies
• 6.6. Global Metastatic Melanoma Therapeutics Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• BRAF Inhibitors
• MEK Inhibitors
• KIT Inhibitors
• 6.7. Global Metastatic Melanoma Therapeutics Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Stereotactic Radiosurgery
• Palliative Radiation Therapy
• 6.8. Global Metastatic Melanoma Therapeutics Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tumor Resection
• Sentinel Lymph Node Biopsy
• Debulking Surgery

7. Metastatic Melanoma Therapeutics Market Regional And Country Analysis

• 7.1. Global Metastatic Melanoma Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Metastatic Melanoma Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Metastatic Melanoma Therapeutics Market

• 8.1. Asia-Pacific Metastatic Melanoma Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Metastatic Melanoma Therapeutics Market

• 9.1. China Metastatic Melanoma Therapeutics Market Overview
• 9.2. China Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Metastatic Melanoma Therapeutics Market

• 10.1. India Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Metastatic Melanoma Therapeutics Market

• 11.1. Japan Metastatic Melanoma Therapeutics Market Overview
• 11.2. Japan Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Metastatic Melanoma Therapeutics Market

• 12.1. Australia Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Metastatic Melanoma Therapeutics Market

• 13.1. Indonesia Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Metastatic Melanoma Therapeutics Market

• 14.1. South Korea Metastatic Melanoma Therapeutics Market Overview
• 14.2. South Korea Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Metastatic Melanoma Therapeutics Market

• 15.1. Western Europe Metastatic Melanoma Therapeutics Market Overview
• 15.2. Western Europe Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Metastatic Melanoma Therapeutics Market

• 16.1. UK Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Metastatic Melanoma Therapeutics Market

• 17.1. Germany Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Metastatic Melanoma Therapeutics Market

• 18.1. France Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Metastatic Melanoma Therapeutics Market

• 19.1. Italy Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Metastatic Melanoma Therapeutics Market

• 20.1. Spain Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Metastatic Melanoma Therapeutics Market

• 21.1. Eastern Europe Metastatic Melanoma Therapeutics Market Overview
• 21.2. Eastern Europe Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Metastatic Melanoma Therapeutics Market

• 22.1. Russia Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Metastatic Melanoma Therapeutics Market

• 23.1. North America Metastatic Melanoma Therapeutics Market Overview
• 23.2. North America Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Metastatic Melanoma Therapeutics Market

• 24.1. USA Metastatic Melanoma Therapeutics Market Overview
• 24.2. USA Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Metastatic Melanoma Therapeutics Market

• 25.1. Canada Metastatic Melanoma Therapeutics Market Overview
• 25.2. Canada Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Metastatic Melanoma Therapeutics Market

• 26.1. South America Metastatic Melanoma Therapeutics Market Overview
• 26.2. South America Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Metastatic Melanoma Therapeutics Market

• 27.1. Brazil Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Metastatic Melanoma Therapeutics Market

• 28.1. Middle East Metastatic Melanoma Therapeutics Market Overview
• 28.2. Middle East Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Metastatic Melanoma Therapeutics Market

• 29.1. Africa Metastatic Melanoma Therapeutics Market Overview
• 29.2. Africa Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Metastatic Melanoma Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Metastatic Melanoma Therapeutics Market Competitive Landscape
• 30.2. Metastatic Melanoma Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Metastatic Melanoma Therapeutics Market Other Major And Innovative Companies

• 31.1. Bristol-Myers Squibb Company
• 31.2. AstraZeneca PLC
• 31.3. GlaxoSmithKline PLC
• 31.4. Takeda Pharmaceutical Company Limited
• 31.5. Eli Lilly and Company
• 31.6. Amgen Inc.
• 31.7. Regeneron Pharmaceuticals Inc.
• 31.8. Daiichi Sankyo Company Ltd.
• 31.9. Eisai Co. Ltd.
• 31.10. Incyte Corporation
• 31.11. Exelixis Inc.
• 31.12. BeiGene Ltd
• 31.13. Immunocore Holdings plc
• 31.14. Genentech Inc.
• 31.15. Iovance Biotherapeutics Inc.

32. Global Metastatic Melanoma Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Metastatic Melanoma Therapeutics Market

34. Recent Developments In The Metastatic Melanoma Therapeutics Market

35. Metastatic Melanoma Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Metastatic Melanoma Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Metastatic Melanoma Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Metastatic Melanoma Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer